These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 15172122)
1. eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Tong X; Li H Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122 [TBL] [Abstract][Full Text] [Related]
2. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Shankar S; Singh TR; Srivastava RK Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092 [TBL] [Abstract][Full Text] [Related]
3. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
4. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926 [TBL] [Abstract][Full Text] [Related]
5. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415 [TBL] [Abstract][Full Text] [Related]
6. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
7. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
9. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
11. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Voelkel-Johnson C; King DL; Norris JS Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Zhang L; Fang B Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937 [TBL] [Abstract][Full Text] [Related]
13. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
14. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
16. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781 [TBL] [Abstract][Full Text] [Related]
17. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Cho YL; Lee KS; Lee SJ; Namkoong S; Kim YM; Lee H; Ha KS; Han JA; Kwon YG; Kim YM Biochem Biophys Res Commun; 2005 Jan; 326(4):752-8. PubMed ID: 15607733 [TBL] [Abstract][Full Text] [Related]
18. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639 [TBL] [Abstract][Full Text] [Related]
19. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Nam SY; Amoscato AA; Lee YJ Oncogene; 2002 Jan; 21(3):337-46. PubMed ID: 11821946 [TBL] [Abstract][Full Text] [Related]
20. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Eid MA; Lewis RW; Abdel-Mageed AB; Kumar MV Int J Oncol; 2002 Jul; 21(1):111-7. PubMed ID: 12063557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]